PT - JOURNAL ARTICLE AU - Sam Moore AU - Edward M. Hill AU - Michael J. Tildesley AU - Louise Dyson AU - Matt J. Keeling TI - Vaccination and Non-Pharmaceutical Interventions: When can the UK relax about COVID-19? AID - 10.1101/2020.12.27.20248896 DP - 2021 Jan 01 TA - medRxiv PG - 2020.12.27.20248896 4099 - http://medrxiv.org/content/early/2021/01/02/2020.12.27.20248896.short 4100 - http://medrxiv.org/content/early/2021/01/02/2020.12.27.20248896.full AB - The announcement of efficacious vaccine candidates against SARS-CoV-2 has been met with worldwide acclaim and relief. Many countries already have detailed plans for vaccine targeting based on minimising severe illness, death and healthcare burdens. Normally, relatively simple relationships between epidemiological parameters, vaccine efficacy and vaccine uptake predict the success of any immunisation programme. However, the dynamics of vaccination against SARS-CoV-2 is made more complex by age-dependent factors, changing levels of infection and the potential relaxation of non-pharmaceutical interventions (NPIs) as the perceived risk declines. In this study we use an age-structured mathematical model, matched to a range of epidemiological data, to consider the interaction between the UK vaccination programme and future relaxation (or removal) of NPIs. Our predictions highlight the population-level risks of early relaxation leading to a pronounced wave of infections, and the individual-level risk relative to vaccine status. While the novel vaccines against SARS-CoV-2 offer a potential exit strategy for this outbreak, this is highly contingent on the transmission blocking action of the vaccine and the population uptake, both of which need to be carefully monitored as vaccine programmes are rolled out in the UK and other countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the National Institute for Health Research (NIHR) [Policy Research Programme, Mathematical \& Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response; NIHR200411], the Medical Research Council through the COVID-19 Rapid Response Rolling Call [grant number MR/V009761/1] and through the JUNIPER modelling consortium [grant number EP/V030477/1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the funders. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data were supplied from the CHESS database after anonymisation under strict data protection protocols agreed between the University of Warwick and Public Health England. The ethics of the use of these data for these purposes was agreed by Public Health England with the Governments SPI-M(O) and SAGE committees.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data were supplied from the CHESS database after anonymisation under strict data protection protocols agreed between the University of Warwick and Public Health England.